Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • novartis

    Tag: novartis

    You Searched For "novartis"
    SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

    SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

    Medical Dialogues Bureau31 Oct 2019 4:15 AM GMT
    Novartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings c...
    GSK ovarian cancer drug Zejula gets USFDA nod for wider use

    GSK ovarian cancer drug Zejula gets USFDA nod for wider use

    Medical Dialogues Bureau24 Oct 2019 4:30 AM GMT
    Zejula was the lead compound of U.S. cancer specialist Tesaro, which GSK acquired for $5.1 billion last year. Zejula brought in sales of 57 million pou...
    GSK to sell anti-rabies vaccines Rabipur, Encepur to Bavarian Nordic for USD 1.1 billion

    GSK to sell anti-rabies vaccines Rabipur, Encepur to Bavarian Nordic for USD 1.1 billion

    Medical Dialogues Bureau22 Oct 2019 4:30 AM GMT
    The sale of GSK's anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, to the Denmark-based biotechnology fir...
    Carcinogen in popular heartburn drug Zantac triggers safety review by European, US regulators

    Carcinogen in popular heartburn drug Zantac triggers safety review by European, US regulators

    Medical Dialogues Bureau14 Sep 2019 3:45 AM GMT
    Valisure said in its report that it found the impurity in both Sanofi SA's branded Zantac as well as generic versions of the drug. But the FDA would no...
    Jubilant Life appoints Novartis Syed Kazmi as President, CEO of its new biotech startup

    Jubilant Life appoints Novartis Syed Kazmi as President, CEO of its new biotech startup

    Medical Dialogues Bureau11 Sep 2019 3:55 AM GMT
    Dr Syed Kazmi joins from Novartis Pharmaceuticals Corporation where he was Vice President, Global Head of Business Development & Licensing for Onco...
    Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer

    Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer

    Medical Dialogues Bureau8 Sep 2019 3:55 AM GMT
    Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cel...
    Cigna new plan to cover expensive gene therapies including Novartis Zolgensma, Luxturna

    Cigna new plan to cover expensive gene therapies including Novartis Zolgensma, Luxturna

    Medical Dialogues Bureau8 Sep 2019 3:30 AM GMT
    The first two gene therapies to be included in Cigna Corp's program are blindness therapy, Luxturna, and the most expensive drug in the world Novartis'...
    Fight for Vildagliptin: Natco goes to court against Novartis

    Fight for Vildagliptin: Natco goes to court against Novartis

    Farhat Nasim7 Sep 2019 11:02 AM GMT
    Mumbai: Throwing an indirect challenge at patent holder Novartis, drugmaker Natco Pharma has submitted a fresh application in a Hyderabad court...
    Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales

    Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales

    Medical Dialogues Bureau7 Sep 2019 3:45 AM GMT
    Roche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for ...
    Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm

    Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm

    Medical Dialogues Bureau5 Sep 2019 3:45 AM GMT
    ZURICH: Novartis sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss ...
    Lindsay Goldberg to buy Bilcare Research in a deal worth USD 279-334 million: Report

    Lindsay Goldberg to buy Bilcare Research in a deal worth USD 279-334 million: Report

    Medical Dialogues Bureau5 Sep 2019 3:30 AM GMT
    Bilcare Research, which employs 1000 staff and has annual sales of 300 million euros, produces plastic packaging used in the pharmaceutical, consumer g...
    Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals

    Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals

    Medical Dialogues Bureau3 Sep 2019 4:00 AM GMT
    Novartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of Bio...
    PrevNext

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 27 May 2022 6:45 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
    verify here.

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X